Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Tjalf Ziemssen - , Department of Neurology (Author)
  • Ann D. Bass - (Author)
  • Regina Berkovich - (Author)
  • Giancarlo Comi - (Author)
  • Sara Eichau - (Author)
  • Jeremy Hobart - (Author)
  • Samuel F Hunter - (Author)
  • Christopher LaGanke - (Author)
  • Volker Limmroth - (Author)
  • Daniel Pelletier - (Author)
  • Carlo Pozzilli - (Author)
  • Sven Schippling - (Author)
  • Livia Sousa - (Author)
  • Anthony Traboulsee - (Author)
  • Bernard M. J. Uitdehaag - (Author)
  • Bart Van Wijmeersch - (Author)
  • Zia Choudhry - (Author)
  • Nadia Daizadeh - (Author)
  • Barry A. Singer - (Author)

Details

Original languageEnglish
JournalCNS drugs
Publication statusPublished - 24 Sept 2020
Peer-reviewedYes

External IDs

Scopus 85088573106

Keywords